OBJECTIVE: • Not only has a precise characterization of libido and sexual arousal in men as a central neural process been lacking, but the interactive role of gonadal hormones and sexual orientation in such processes has never been investigated. We investigate the relationships among sexual hormones, sexual arousal, and sexual orientation in men by comparing the self-reported sexual response of heterosexual and homosexual men with locally advanced prostate neoplasm, receiving the non-steroidal anti-androgen bicalutamide as monotherapy. PATIENTS AND METHODS: • 29 Romanian men participated in this study: 17 heterosexual and 12 homosexual. Patients were undergoing treatment for prostate cancer consisting of a standard daily dose of 50 mg bicalutamide, a fast acting non-steroidal anti-androgen with action comparable to other anti-androgen drugs but with reportedly fewer sexual side effects. • Patients retrospectively provided information regarding their sexual functioning measured by the IIEF prior to commencing bicalutamide treatment. • Then, about five weeks later, patients were asked to prospectively provide information regarding their current sexual functioning while undergoing bicalutamide treatment. RESULTS: • Overall IIEF scores as well as the Erectile Function, Orgasmic Function, Sexual Desire, and Overall Satisfaction subscales showed group, treatment, and group by treatment effects. • The Intercourse Satisfaction subscale showed group and group by treatment effects. • On most subscales, homosexual men showed lower functioning than heterosexual men, primarily in response to treatment with bicalutamide. CONCLUSIONS: • Treatment with an anti-androgen in a clinical population of men undergoing therapy for prostate cancer affected homosexual men more than heterosexual men, although not all heterosexual men were unaffected. • These results are discussed in the context of dual sexual natures, a concept recently developed in the sexual literature. • Furthermore, these findings reiterate the importance of incorporating such variables as sexual orientation into studies investigating medical treatments on sexual response.
OBJECTIVE: • Not only has a precise characterization of libido and sexual arousal in men as a central neural process been lacking, but the interactive role of gonadal hormones and sexual orientation in such processes has never been investigated. We investigate the relationships among sexual hormones, sexual arousal, and sexual orientation in men by comparing the self-reported sexual response of heterosexual and homosexual men with locally advanced prostate neoplasm, receiving the non-steroidal anti-androgen bicalutamide as monotherapy. PATIENTS AND METHODS: • 29 Romanian men participated in this study: 17 heterosexual and 12 homosexual. Patients were undergoing treatment for prostate cancer consisting of a standard daily dose of 50 mg bicalutamide, a fast acting non-steroidal anti-androgen with action comparable to other anti-androgen drugs but with reportedly fewer sexual side effects. • Patients retrospectively provided information regarding their sexual functioning measured by the IIEF prior to commencing bicalutamide treatment. • Then, about five weeks later, patients were asked to prospectively provide information regarding their current sexual functioning while undergoing bicalutamide treatment. RESULTS: • Overall IIEF scores as well as the Erectile Function, Orgasmic Function, Sexual Desire, and Overall Satisfaction subscales showed group, treatment, and group by treatment effects. • The Intercourse Satisfaction subscale showed group and group by treatment effects. • On most subscales, homosexual men showed lower functioning than heterosexual men, primarily in response to treatment with bicalutamide. CONCLUSIONS: • Treatment with an anti-androgen in a clinical population of men undergoing therapy for prostate cancer affected homosexual men more than heterosexual men, although not all heterosexual men were unaffected. • These results are discussed in the context of dual sexual natures, a concept recently developed in the sexual literature. • Furthermore, these findings reiterate the importance of incorporating such variables as sexual orientation into studies investigating medical treatments on sexual response.
Authors: Gwendolyn P Quinn; Julian A Sanchez; Steven K Sutton; Susan T Vadaparampil; Giang T Nguyen; B Lee Green; Peter A Kanetsky; Matthew B Schabath Journal: CA Cancer J Clin Date: 2015-07-17 Impact factor: 508.702
Authors: Elizabeth J Polter; Christopher W Wheldon; B R Simon Rosser; Nidhi Kohli; Benjamin D Capistrant; Aditya Kapoor; Badrinath Konety; Darryl Mitteldorf; Michael Ross; Kristine M C Talley; Loren Terveen; William West; Morgan M Wright Journal: Psychooncology Date: 2019-11-11 Impact factor: 3.894
Authors: Ion G Motofei; David L Rowland; Mirela Manea; Simona R Georgescu; Ioana Păunică; Ioanel Sinescu Journal: Clin Drug Investig Date: 2017-06 Impact factor: 2.859
Authors: B R Simon Rosser; Benjamin Capistrant; Maria Beatriz Torres; Badrinath Konety; Enyinnaya Merengwa; Darryl Mitteldorf; William West Journal: Sex Relation Ther Date: 2016-08-29
Authors: Nir Kleinmann; Nicholas G Zaorsky; Timothy N Showalter; Leonard G Gomella; Costas D Lallas; Edouard J Trabulsi Journal: Nat Rev Urol Date: 2012-04-10 Impact factor: 14.432
Authors: B R Simon Rosser; Nidhi Kohli; Lindsey Lesher; Benjamin D Capistrant; James DeWitt; Gunna Kilian; Badrinath R Konety; Enyinnaya Merengwa; Darryl Mitteldorf; William West Journal: Urol Pract Date: 2017-04-21
Authors: Tae L Hart; David W Coon; Marc A Kowalkowski; Karen Zhang; Justin I Hersom; Heather H Goltz; Daniela A Wittmann; David M Latini Journal: J Sex Med Date: 2014-05-30 Impact factor: 3.802
Authors: B R Simon Rosser; Shanda L Hunt; Benjamin D Capistrant; Nidhi Kohli; Badrinath R Konety; Darryl Mitteldorf; Michael W Ross; Kristine M Talley; William West Journal: Curr Sex Health Rep Date: 2019-11-08